Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45

1.

Preservation of Fertility or Ovarian Function in Patients with Breast Cancer or Gynecologic and Internal Malignancies.

Stachs A, Hartmann S, Gerber B.

Geburtshilfe Frauenheilkd. 2017 Aug;77(8):861-869. doi: 10.1055/s-0043-116222. Epub 2017 Aug 24.

2.

Protecting Effects of Gonadotropin-Releasing Hormone Agonist on Chemotherapy-Induced Ovarian Damage in Premenopausal Breast Cancer Patients: A Systematic Review and Meta-Analysis.

Bai F, Lu Y, Wu K, Chen Q, Ding L, Ge M, Weng Z.

Breast Care (Basel). 2017 Mar;12(1):48-52. doi: 10.1159/000454983. Epub 2017 Feb 28. Review.

PMID:
28611542
3.

Melatonin and Fertoprotective Adjuvants: Prevention against Premature Ovarian Failure during Chemotherapy.

Jang H, Hong K, Choi Y.

Int J Mol Sci. 2017 Jun 7;18(6). pii: E1221. doi: 10.3390/ijms18061221. Review.

4.

Effects of Bushen Tianjing Recipe in a rat model of tripterygium glycoside-induced premature ovarian failure.

Xu X, Tan Y, Jiang G, Chen X, Lai R, Zhang L, Liang G.

Chin Med. 2017 Apr 24;12:10. doi: 10.1186/s13020-017-0131-3. eCollection 2017.

5.

Up the Duff With Non-Hodgkin's Lymphoma: The Traumas and the Dilemmas.

Marwah S, Gaikwad HS, Mohindra R, Sharma M.

J Clin Diagn Res. 2017 Feb;11(2):QD03-QD05. doi: 10.7860/JCDR/2017/23972.9221. Epub 2017 Feb 1.

6.

Fertility-preservation in endometrial cancer: is it safe? Review of the literature.

Carneiro MM, Lamaita RM, Ferreira MC, Silva-Filho AL.

JBRA Assist Reprod. 2016 Dec 1;20(4):232-239. doi: 10.5935/1518-0557.20160045. Review.

7.

Reproductive issues in patients undergoing Hematopoietic Stem Cell Transplantation: an update.

Guida M, Castaldi MA, Rosamilio R, Giudice V, Orio F, Selleri C.

J Ovarian Res. 2016 Nov 1;9(1):72. Review.

8.

Preserving Fertility in Children and Adolescents with Cancer.

Levine JM.

Children (Basel). 2014 Aug 26;1(2):166-85. doi: 10.3390/children1020166. Review.

9.

Ovarian function after hematopoietic cell transplantation: a descriptive study following the use of GnRH agonists for myeloablative conditioning and observation only for reduced-intensity conditioning.

Phelan R, Mann E, Napurski C, DeFor TE, Petryk A, Miller WP, Wagner JE, Verneris MR, Smith AR.

Bone Marrow Transplant. 2016 Oct;51(10):1369-1375. doi: 10.1038/bmt.2016.150. Epub 2016 Jun 6.

10.

Goserelin, as an ovarian protector during (neo)adjuvant breast cancer chemotherapy, prevents long term altered bone turnover.

Wilson C, Gossiel F, Leonard R, Anderson RA, Adamson DJ, Thomas G, Coleman RE.

J Bone Oncol. 2016 Feb 11;5(1):43-9. doi: 10.1016/j.jbo.2016.02.003. eCollection 2016 Mar.

11.

Fertility preservation in young patients with cancer.

Suhag V, Sunita BS, Sarin A, Singh AK, Dashottar S.

South Asian J Cancer. 2015 Jul-Sep;4(3):134-9. doi: 10.4103/2278-330X.173175. Review.

12.

Cancer and fertility preservation: international recommendations from an expert meeting.

Lambertini M, Del Mastro L, Pescio MC, Andersen CY, Azim HA Jr, Peccatori FA, Costa M, Revelli A, Salvagno F, Gennari A, Ubaldi FM, La Sala GB, De Stefano C, Wallace WH, Partridge AH, Anserini P.

BMC Med. 2016 Jan 4;14:1. doi: 10.1186/s12916-015-0545-7.

13.

Utility of gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage in premenopausal women with breast cancer: a systematic review and meta-analysis.

Shen YW, Zhang XM, Lv M, Chen L, Qin TJ, Wang F, Yang J, Liu PJ, Yang J.

Onco Targets Ther. 2015 Nov 13;8:3349-59. doi: 10.2147/OTT.S95936. eCollection 2015.

14.

Gonadotropin-Releasing Hormone Agonists for Ovarian Function Preservation in Premenopausal Women Undergoing Chemotherapy for Early-Stage Breast Cancer: A Systematic Review and Meta-analysis.

Munhoz RR, Pereira AA, Sasse AD, Hoff PM, Traina TA, Hudis CA, Marques RJ.

JAMA Oncol. 2016 Jan;2(1):65-73. doi: 10.1001/jamaoncol.2015.3251. Review.

15.

Fertility preservation in reproductive-age women facing gonadotoxic treatments.

Roberts J, Ronn R, Tallon N, Holzer H.

Curr Oncol. 2015 Aug;22(4):e294-304. doi: 10.3747/co.22.2334.

16.

Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.

Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow J, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian L, Meyskens FL Jr, Gelber RD, Hortobagyi GN, Albain KS; POEMS/S0230 Investigators.

N Engl J Med. 2015 Mar 5;372(10):923-32. doi: 10.1056/NEJMoa1413204.

17.

Fertility status of Hodgkin lymphoma patients treated with chemotherapy and adjuvant gonadotropin-releasing hormone analogues.

Huser M, Smardova L, Janku P, Crha I, Zakova J, Stourac P, Jarkovsky J, Mayer J, Ventruba P.

J Assist Reprod Genet. 2015 Aug;32(8):1187-93. doi: 10.1007/s10815-015-0452-z. Epub 2015 Feb 28.

18.

Fertility issues of breast cancer survivors.

McClellan Misiewicz H.

J Adv Pract Oncol. 2012 Sep;3(5):289-98. Review.

19.

Utility of GnRH-agonists for Fertility Preservation in Women With Operable Breast Cancer: Is It Protective?

Bedoschi G, Turan V, Oktay K.

Curr Breast Cancer Rep. 2013 Dec 1;5(4):302-308.

20.

Fertility preservation in gynecological cancers.

Chhabra S, Kutchi I.

Clin Med Insights Reprod Health. 2013 Mar 21;7:49-59. doi: 10.4137/CMRH.S10794. eCollection 2013 Mar 21. Review.

Supplemental Content

Support Center